Next Article in Journal
Orally Disintegrating Tablets Containing Melt Extruded Amorphous Solid Dispersion of Tacrolimus for Dissolution Enhancement
Next Article in Special Issue
Chitosan Glutamate-Coated Niosomes: A Proposal for Nose-to-Brain Delivery
Previous Article in Journal
Hyaluronic Acid Decorated Naringenin Nanoparticles: Appraisal of Chemopreventive and Curative Potential for Lung Cancer
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview
Pharmaceutics 2018, 10(1), 34; https://doi.org/10.3390/pharmaceutics10010034

Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting

1
Interdipartmental Center for Innovation in Health Products, BIOPHARMANET TEC, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy
2
Food and Drug Department, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy
3
Department of Life Sciences and Biotechnology, University of Ferrara, Via Fossato di Mortara 17/19, 44121 Ferrara, Italy
4
Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre 90610-000, Brazil
5
Departamento de Química Orgânica, Instituto de Química, Universidade Federal do Rio Grande do Sul, Porto Alegre 91501-970, Brazil
*
Author to whom correspondence should be addressed.
Received: 8 February 2018 / Revised: 10 March 2018 / Accepted: 12 March 2018 / Published: 15 March 2018
(This article belongs to the Special Issue Nose to Brain Delivery)
Full-Text   |   PDF [4708 KB, uploaded 15 March 2018]   |  

Abstract

In the field of nasal drug delivery, nose-to-brain delivery is among the most fascinating applications, directly targeting the central nervous system, bypassing the blood brain barrier. Its benefits include dose lowering and direct brain distribution of potent drugs, ultimately reducing systemic side effects. Recently, nasal administration of insulin showed promising results in clinical trials for the treatment of Alzheimer’s disease. Nanomedicines could further contribute to making nose-to-brain delivery a reality. While not disregarding the need for devices enabling a formulation deposition in the nose’s upper part, surface modification of nanomedicines appears the key strategy to optimize drug delivery from the nasal cavity to the brain. In this review, nanomedicine delivery based on particle engineering exploiting surface electrostatic charges, mucoadhesive polymers, or chemical moieties targeting the nasal epithelium will be discussed and critically evaluated in relation to nose-to-brain delivery. View Full-Text
Keywords: nose-to-brain delivery; nanoparticles; pharmaceutical nanotechnology; mucoadhesion; mucus-penetrating particles; targeting; CNS disorders; neurodegenerative diseases; Alzheimer’s disease; Parkinson’s disease nose-to-brain delivery; nanoparticles; pharmaceutical nanotechnology; mucoadhesion; mucus-penetrating particles; targeting; CNS disorders; neurodegenerative diseases; Alzheimer’s disease; Parkinson’s disease
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Sonvico, F.; Clementino, A.; Buttini, F.; Colombo, G.; Pescina, S.; Stanisçuaski Guterres, S.; Raffin Pohlmann, A.; Nicoli, S. Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting. Pharmaceutics 2018, 10, 34.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top